SECsense Logo

Adial Pharmaceuticals 8-K Report: Key Insights & Financial Updates

$ADIL
Form 8-K
Filed on: 2024-12-18
Source
Adial Pharmaceuticals 8-K Report: Key Insights & Financial Updates

Based on the provided section of the financial report, here are the key insights and information extracted:

  1. Entity Information:
  • Company Name: Adial Pharmaceuticals, Inc.
  • CIK (Central Index Key): 0001513525
  • SEC File Number: 001-38323
  • EIN (Employer Identification Number): 82-3074668
  • Address: 4870 Sadler Road, Ste 300, Glen Allen, VA 23060
  • Phone Number: 804-487-8196
  1. Document Type:
  • Filing Type: 8-K Report
  • Filing Date: December 13, 2024
  1. Financial Information:
  • Reporting Period: The financial data is as of December 13, 2024 (the start and end date of the reporting period are the same).
  • Currency: All financial figures are presented in US Dollars (USD).
  • Measurement Units: The report includes data measured in both USD and shares.
  1. Stock Information:
  • Common Stock Symbol: ADIL
  • Stock Exchange: NASDAQ
  1. XML and XBRL Aspects:
  • The document is structured in XBRL format, which is used for electronic filing and reporting of financial data.

Insights:

  • The report indicates that Adial Pharmaceuticals, Inc. is actively filing an 8-K, which is typically used to announce major events that shareholders should know about, implying potential developments or changes within the company.
  • The absence of additional details in the provided section suggests that this may be a preliminary filing or that the details are captured in subsequent sections of the full report. Further analysis would require additional context from the complete document.